BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive ...
AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...
The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...
Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.
7hon MSN
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
Hosted on MSN7h
What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 EarningsWall Street analysts forecast that Bristol Myers Squibb (BMY) will report quarterly earnings of $1.46 per share in its upcoming release, pointing to a year-over-year decline of 14.1%. It is ...
Bristol Neuroscience will be hosting a number of high-profile speakers for the 2024-25 academic year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback